Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC

⟵ Back to Search Results

Beigene Study ID

BGB-A317-301

ClinicalTrials.gov ID

NCT03412773

EudraCT Number

2017-002423-19

China Drug Trials ID

CTR20170882

Sex: All

Age: 18 Years / N/A

No Study Documents

Sex: All

Age: 18 Years / N/A

No Study Documents